Serum uri acid: Neuroprotection in thrombolysis. The Bergen NORSTROKE study

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Logallo, Nicola ^a,b   Naess, Halvor ^a   Idicula, Titto T ^a   Brogger, Jan ^a   Waje Andreassen, Ulrike ^a   Thomassen, Lars ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

NATEPLASE; URIC ACID; NEUROPROTECTIVE AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CLINICAL FEATURE; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; RISK FACTOR; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; AGED; BLOOD; COMPARATIVE STUDY; FIBRINOLYTIC THERAPY; HOSPITALIZATION; METHODOLOGY; NORWAY; PROSPECTIVE STUDY; STATISTICS; STROKE; TIME;

AGED; BRAIN ISCHEMIA; FEMALE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; NORWAY; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; URIC ACID;

EID: 80053172057     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-114     Document Type: Article

References (29)

1. Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med 1993, 14(6):615-631. 10.1016/0891-5849(93)90143-I, 8325534.
2. Sinha S, Singh SN, Ray US. Total antioxidant status at high altitude in lowlanders and native highlanders: role of uric acid. High Alt Med Biol 2009, 10(3):269-274. 10.1089/ham.2008.1082, 19775217.
3. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 1998, 53(5):613-625. 10.1002/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1, 9726432.
4. Romanos E, Planas AM, Amaro S, Chamorro A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 2007, 27(1):14-20. 10.1038/sj.jcbfm.9600312, 16596120.
5. Chamorro A, Obach V, Cervera A, Revilla M, Deulofeu R, Aponte JH. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 2002, 33(4):1048-1052. 10.1161/hs0402.105927, 11935059.
6. Hong JM, Bang OY, Chung CS, Joo IS, Gwag BJ, Ovbiagele B. Influence of recanalization on uric acid patterns in acute ischemic stroke. Cerebrovasc Dis 2010, 29(5):431-439. 10.1159/000289346, 20203485.
7. Brouns R, Wauters A, Van De Vijver G, De Surgeloose D, Sheorajpanday R, De Deyn PP. Decrease in uric acid in acute ischemic stroke correlates with stroke severity, evolution and outcome. Clin Chem Lab Med 2010, 48(3):383-390. 10.1515/CCLM.2010.065, 20020821.
8. Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke 2007, 38(7):2173-2175. 10.1161/STROKEAHA.106.480699, 17525395.
9. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension 2003, 41(6):1183-1190. 10.1161/01.HYP.0000069700.62727.C5, 12707287.
10. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003, 18(6):523-530.
11. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008, 359(17):1811-1821. 10.1056/NEJMra0800885, 2684330, 18946066.
12. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003, 34(8):1951-1956. 10.1161/01.STR.0000081983.34771.D2, 12843346.
13. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008, 25(5):457-507.
14. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007, 369(9558):275-282. 10.1016/S0140-6736(07)60149-4, 17258667.
15. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989, 20(7):864-870. 10.1161/01.STR.20.7.864, 2749846.
16. Prabhakaran S, Chen M, Choi JH, Mangla S, Lavine SD, Pile-Spellman J, Meyers PM, Chong JY. Major neurologic improvement following endovascular recanalization therapy for acute ischemic stroke. Cerebrovasc Dis 2008, 25(5):401-407. 10.1159/000121340, 18349533.
17. Nam HS, Lee KY, Han SW, Kim SH, Lee JY, Ahn SH, Kim DJ, Kim DI, Nam CM, Heo JH. Prediction of long-term outcome by percent improvement after the first day of thrombolytic treatment in stroke patients. J Neurol Sci 2009, 281(1-2):69-73. 10.1016/j.jns.2009.02.365, 19304298.
18. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24(1):35-41. 10.1161/01.STR.24.1.35, 7678184.
19. Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007, 38(3):1091-1096. 10.1161/01.STR.0000258355.23810.c6, 17272767.
20. Sulter G, Steen C, De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999, 30(8):1538-1541. 10.1161/01.STR.30.8.1538, 10436097.
21. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 2008, 39(6):1751-1758. 10.1161/STROKEAHA.107.503334, 18369171.
22. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004, 1(1):36-45. 10.1602/neurorx.1.1.36, 534911, 15717006.
23. Ryan M, Grayson L, Clarke DJ. The total antioxidant capacity of human serum measured using enhanced chemiluminescence is almost completely accounted for by urate. Ann Clin Biochem 1997, 34(Pt 6):688-689.
24. Proctor PH. Uric acid: neuroprotective or neurotoxic?. Stroke 2008, 39(5):e88. author reply e89, 10.1161/STROKEAHA.107.513242, 18369163.
25. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008, 27(6):608-619. 10.1080/15257770802138558, 2895915, 18600514.
26. Zivin JA, Mazzarella V. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol 1991, 48(12):1235-1238.
27. Bowes MP, Rothlein R, Fagan SC, Zivin JA. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 1995, 45(4):815-819.
28. Amaro S, Urra X, Gomez-Choco M, Obach V, Cervera A, Vargas M, Torres F, Rios J, Planas AM, Chamorro A. Uric acid levels are relevant in patients with stroke treated with thrombolysis. Stroke 2011, 42(1 Suppl):S28-32.
29. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 2004, 61(3):461-470. 10.1016/j.cardiores.2003.10.025, 14962477.